The tubeless insulin pump specialist's revenue growth slowed notably in the second quarter, but management said this is a short-term phenomenon related to the company's transition to a direct sales model in Europe.
Don't be caught off-guard: Insulet (NASDAQ: PODD) releases its next round of earnings Thursday. Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters guide for Thursday's Q2 earnings...
Insulet Corporation (NASDAQ: PODD) is up 80.5 percent year-over-year, and even last quarter’s bottom-line miss can’t deter the biotech’s bulls.
BMO Capital Markets analyst Joanne Wuensch initiated coverage of Insulet Corp....
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Insulet (PODD):
Insulet (PODD) is competing against Mini Med, a division of Medtronic, for the insulin delivery system segment. The product has a needle which is inserted until an audible sound is heard, then the needle withdraws leaving behind a tethlon tube. Insuline is dripped from the pod into the body via the tube. When the pod is low on the solution, more is added. This avoids the nasty needle sticks many diabetics loath.
The pod can be worn many places on the body and has no major tubes of complicated computer readouts, vs. the typical insulin pump.
Often a physician asks the patient to try wearing the pod while it drips saline. Uptake is high afterwards as the pod is so comfortable.
Per the CEO, Duane Desisto, they may have a pump company burried in a pod company. Meaning that other drugs may be delivered via the pod.